Orphan enzymes could be an unexplored reservoir of new drug targets
| Autor: | Bernard Labedan, Olivier Lespinet |
|---|---|
| Přispěvatelé: | Institut de génétique et microbiologie [Orsay] (IGM), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS) |
| Rok vydání: | 2006 |
| Předmět: |
Drug
media_common.quotation_subject Genomics Computational biology Biology 03 medical and health sciences 0302 clinical medicine Pharmaceutical technology Sequence Analysis Protein [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN] Drug Discovery Animals Humans Enzyme Inhibitors 030304 developmental biology Sequence (medicine) media_common Pharmacology chemistry.chemical_classification 0303 health sciences business.industry Enzyme Commission number Enzymes Biotechnology Enzyme chemistry Drug Design business Biochemical function 030217 neurology & neurosurgery Wide gap |
| Zdroj: | Drug discovery today. Drug discovery today., 2006, 11, pp.300-5 |
| ISSN: | 1359-6446 |
| Popis: | Despite the immense progress of genomics, and the current availability of several hundreds of thousands of amino acid sequences, >39% of well-defined enzyme activities (as represented by enzyme commission, EC, numbers) are not associated with any sequence. There is an urgent need to explore the 1525 orphan enzymes (enzymes having EC numbers without an associated sequence) to bridge the wide gap that separates knowledge of biochemical function and sequence information. Strikingly, orphan enzymes can even be found among enzymatic activities successfully used as drug targets. Here, knowledge of sequence would help to develop molecular-targeted therapies, suppressing many drug-related side-effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect